Xencor

Anatomy of an optimized antibody. Blue indicates sites for potential engineering.

XmAb™ technologies are a suite of proprietary antibody Fc domains and antibody engineering tools that enable the creation, with Xencor technology alone, of humanized therapeutic antibody candidates with significantly enhanced potency, half-life, affinity and ease of production. We created these capabilities using our PDA® computational amino acid sequence design tools.

Enhancing Fc Effector Function

One of our suite of PDA® technologies, XmAb™ antibody technology is helping Xencor fill the substantial demand for structural and functional optimization of monoclonal antibodies as cytotoxic agents. Although hailed as "magic bullets", the ability of antibodies to destroy targeted tumor cells is suboptimal. Using XmAb™ engineered Fc domains, we are giving antibodies more tumor killing power by greatly improving their capacity to recruit the immune system against cancer cells.

Enhanced Half-life Antibodies

We have engineered Fc domains to significantly enhance the in vivo half-life of monoclonal antibodies, which has the potential to enable new dosing routes, enhance patient convenience and reduce overall cost of antibody therapies.

Enhanced Affinity Antibodies

We combine our unique approach for optimizing Fc domains with proprietary Fv engineering tools that create a wide range of antigen affinities, including the generation of high-affinity, humanized antibodies, giving Xencor the capability to address all aspects of antibody candidate discovery.

Ease of Production

Our structure-based approach also creates highly soluble and readily expressed antibodies, enabling us to circumvent obstacles that can often delay or halt antibody development. Physical and production characteristics are crucial for advancing candidates to the clinic but are usually not addressed by older antibody design methods.